Skip to main content

Injectafer Side Effects

Generic name: ferric carboxymaltose

Medically reviewed by Drugs.com. Last updated on Oct 14, 2023.

Note: This document contains side effect information about ferric carboxymaltose. Some dosage forms listed on this page may not apply to the brand name Injectafer.

Applies to ferric carboxymaltose: intravenous solution.

Serious side effects of Injectafer

Along with its needed effects, ferric carboxymaltose (the active ingredient contained in Injectafer) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ferric carboxymaltose:

Less common

Incidence not known

Other side effects of Injectafer

Some side effects of ferric carboxymaltose may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Rare

Incidence not known

For Healthcare Professionals

Applies to ferric carboxymaltose: intravenous solution.

Cardiovascular

Common (1% to 10%): Flushing/hot flush, hypertension, hypotension

Uncommon (0.1% to 1%): Chest pain, peripheral edema, tachycardia

Rare (less than 0.1%): Phlebitis

Postmarketing reports: Chest discomfort, pallor[Ref]

Dermatologic

Uncommon (0.1% to 1%): Erythema, rash, pruritus, urticaria

Postmarketing reports: Angioedema, dermatitis[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, vomiting

Uncommon (0.1% to 1%): Abdominal pain, constipation, diarrhea, dyspepsia

Rare (less than 0.1%): Flatulence[Ref]

Hepatic

Common (1% to 10%): Alanine aminotransferase increase

Uncommon (0.1% to 1%): Aspartate aminotransferase increase, gamma glutamyl transferase increase[Ref]

Hypersensitivity

Common (1% to 10%): Pruritus, rash, urticaria, wheezing, and hypertension associated with hypersensitivity reactions

Rare (less than 0.1%): Serious anaphylactic/anaphylactoid reactions[Ref]

Local

Common (1% to 10%): Injection site reactions[Ref]

Injection site reactions include infusion site burning, -pain, -bruising, -discoloration, -extravasation, -irritation, and -paresthesia.[Ref]

Metabolic

Common (1% to 10%): Blood phosphorus decrease, hypophosphatemia

Uncommon (0.1% to 1%): Blood alkaline phosphatase increase, blood lactate dehydrogenase increase[Ref]

Musculoskeletal

Postmarketing reports: Arthralgia, back pain, hypophosphatemic osteomalacia, muscle spasms, myalgia[Ref]

Nervous system

Common (1% to 10%): Dizziness, dysgeusia, headache

Uncommon (0.1% to 1%): Paraesthesia

Rare (less than 0.1%): Syncope, presyncope

Postmarketing reports: Loss of consciousness[Ref]

Other

Uncommon (0.1% to 1%): Chills, fatigue, pain, pyrexia

Rare (less than 0.1%): Malaise, rigors

Frequency not reported: Overestimate of serum iron and transferrin bound iron laboratory assays

Postmarketing reports: Face edema, vertigo[Ref]

Respiratory

Uncommon (0.1% to 1%): Sneezing

Rare (less than 0.1%): Bronchospasm

Postmarketing reports: Dyspnea[Ref]

Psychiatric

Rare (less than 0.1%): Anxiety[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Cerner Multum, Inc. "Australian Product Information."

3. (2013) "Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.